The production of therapeutic proteins in bacteria requires an efficient expression platform, consisting of an adapted bacterial strain and an optimized vector. This platform has to meet the scientific and technical demands of an industrial utilization, as well as fulfill the regulatory requirements of the pharmaceutical industry.

The bacterial expression of peptides is regarding their molar mass affected by high sensitivity for proteolytic degradation in bacterial host cells. Designing fusions of proteins with those peptides can improve the expression of the peptides.

The objective of the project is to investigate the influence of the fusion partners to the expression of the peptides. It concludes the development of an expression vector family for peptide expression in bacteria as well as the selection of suitable proteases for the final release of the target peptide. This also involves choosing a patent-free vector, schedule applicable cloning sites for DNA sequence implementation of the fused target peptide and examination of expression rates of the variants.

This project is partly funded by the European Union, particularly the European Regional Development Fund (ERDF) and REACT-EU as part of the reaction of the Union to the COVID-19 pandemic.

© 2015- Okmed Biotech GmbH

Weinbergweg 23, 06120 Halle (Saale) Germany